Cosmo Pharmaceuticals NV (CHIX:COPNZ) Additional Paid-In Capital : CHF237.6 Mil(As of Jun. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Cosmo Pharmaceuticals NV Additional Paid-In Capital?

Cosmo Pharmaceuticals NV's quarterly additional paid-in capital declined from Jun. 2022 (CHF249.8 Mil) to Dec. 2022 (CHF240.4 Mil) but then stayed the same from Dec. 2022 (CHF240.4 Mil) to Jun. 2023 (CHF237.6 Mil).

Cosmo Pharmaceuticals NV's annual additional paid-in capital increased from Dec. 2020 (CHF91.3 Mil) to Dec. 2021 (CHF253.5 Mil) but then declined from Dec. 2021 (CHF253.5 Mil) to Dec. 2022 (CHF240.4 Mil).

Cosmo Pharmaceuticals NV Additional Paid-In Capital Historical Data

The historical data trend for Cosmo Pharmaceuticals NV's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cosmo Pharmaceuticals NV Additional Paid-In Capital Chart

Cosmo Pharmaceuticals NV Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Additional Paid-In Capital

Get a 7-Day Free Trial

95.30

92.20

91.27

253.47

240.37

Cosmo Pharmaceuticals NV Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Additional Paid-In Capital	Get a 7-Day Free Trial															92.36	253.47	249.80	240.37	237.60

Cosmo Pharmaceuticals NV Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Cosmo Pharmaceuticals NV Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Cosmo Pharmaceuticals NV's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Cosmo Pharmaceuticals NV (CHIX:COPNZ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cosmo Pharmaceuticals NV (CHIX:COPNz) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

CMOPF:USA C43:Germany COPN:Switzerland

Address

Sir John Rogerson’s Quay, Riverside II, Dublin, IRL, 2

Website

https://www.cosmopharma.com

Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology and healthtech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. Product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10 and CB-01-33.

Cosmo Pharmaceuticals NV (CHIX:COPNZ) Headlines

No Headlines